Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma

Detalhes bibliográficos
Autor(a) principal: Ejtehadifar, Mostafa
Data de Publicação: 2023
Outros Autores: Zahedi, Sara, Gameiro, Paula, Cabeçadas, José, da Silva, Maria Gomes, Beck, Hans C., Carvalho, Ana Sofia, Matthiesen, Rune
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/147811
Resumo: Funding: Rune Matthiesen is supported by Fundação para a Ciência e a Tecnologia (CEEC position, 2019–2025 investigator). This article is a Fiigureresult of the projects (iNOVA4Health— UIDB/04462/2020), supported by Lisboa Portugal Regional Operational Programme (Lisboa2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). This work is also funded by FEDER funds through the COMPETE 2020 Programme and National Funds through FCT—Portuguese Foundation for Science and Technology under the project numbers: PTDC/BTM-TEC/30087/2017 and PTDC/BTM-TEC/30088/2017.
id RCAP_84eef82e959d8cd68644fd9344b1a395
oai_identifier_str oai:run.unl.pt:10362/147811
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell LymphomaannexinA5diffuse large B cell lymphomagerminal centerinterferon regulatory factor 4light zonemass-spectrometrynucleobindin1proteomicsBiochemistry, Genetics and Molecular Biology(all)Funding: Rune Matthiesen is supported by Fundação para a Ciência e a Tecnologia (CEEC position, 2019–2025 investigator). This article is a Fiigureresult of the projects (iNOVA4Health— UIDB/04462/2020), supported by Lisboa Portugal Regional Operational Programme (Lisboa2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). This work is also funded by FEDER funds through the COMPETE 2020 Programme and National Funds through FCT—Portuguese Foundation for Science and Technology under the project numbers: PTDC/BTM-TEC/30087/2017 and PTDC/BTM-TEC/30088/2017.The prognosis of diffuse large B cell lymphoma (DLBCL) is inaccurately predicted using clinical features and immunohistochemistry (IHC) algorithms. Nomination of a panel of molecules as the target for therapy and predicting prognosis in DLBCL is challenging because of the divergences in the results of molecular studies. Mass spectrometry (MS)-based proteomics in the clinic represents an analytical tool with the potential to improve DLBCL diagnosis and prognosis. Previous proteomics studies using MS-based proteomics identified a wide range of proteins. To achieve a consensus, we reviewed MS-based proteomics studies and extracted the most consistently significantly dysregulated proteins. These proteins were then further explored by analyzing data from other omics fields. Among all significantly regulated proteins, interferon regulatory factor 4 (IRF4) was identified as a potential target by proteomics, genomics, and IHC. Moreover, annexinA5 (ANXA5) and nucleobindin1 (NUCB1) were two of the most up-regulated proteins identified in MS studies. Functional enrichment analysis identified the light zone reactions of the germinal center (LZ-GC) together with cytoskeleton locomotion functions as enriched based on consistent, significantly dysregulated proteins. In this study, we suggest IRF4 and NUCB1 proteins as potential biomarkers that deserve further investigation in the field of DLBCL sub-classification and prognosis.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNEjtehadifar, MostafaZahedi, SaraGameiro, PaulaCabeçadas, Joséda Silva, Maria GomesBeck, Hans C.Carvalho, Ana SofiaMatthiesen, Rune2023-01-18T22:17:08Z2023-01-032023-01-03T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/147811eng2073-4409PURE: 50623021https://doi.org/10.3390/cells12010196info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-05-22T18:08:18Zoai:run.unl.pt:10362/147811Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-05-22T18:08:18Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma
title Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma
spellingShingle Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma
Ejtehadifar, Mostafa
annexinA5
diffuse large B cell lymphoma
germinal center
interferon regulatory factor 4
light zone
mass-spectrometry
nucleobindin1
proteomics
Biochemistry, Genetics and Molecular Biology(all)
title_short Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma
title_full Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma
title_fullStr Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma
title_full_unstemmed Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma
title_sort Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma
author Ejtehadifar, Mostafa
author_facet Ejtehadifar, Mostafa
Zahedi, Sara
Gameiro, Paula
Cabeçadas, José
da Silva, Maria Gomes
Beck, Hans C.
Carvalho, Ana Sofia
Matthiesen, Rune
author_role author
author2 Zahedi, Sara
Gameiro, Paula
Cabeçadas, José
da Silva, Maria Gomes
Beck, Hans C.
Carvalho, Ana Sofia
Matthiesen, Rune
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
RUN
dc.contributor.author.fl_str_mv Ejtehadifar, Mostafa
Zahedi, Sara
Gameiro, Paula
Cabeçadas, José
da Silva, Maria Gomes
Beck, Hans C.
Carvalho, Ana Sofia
Matthiesen, Rune
dc.subject.por.fl_str_mv annexinA5
diffuse large B cell lymphoma
germinal center
interferon regulatory factor 4
light zone
mass-spectrometry
nucleobindin1
proteomics
Biochemistry, Genetics and Molecular Biology(all)
topic annexinA5
diffuse large B cell lymphoma
germinal center
interferon regulatory factor 4
light zone
mass-spectrometry
nucleobindin1
proteomics
Biochemistry, Genetics and Molecular Biology(all)
description Funding: Rune Matthiesen is supported by Fundação para a Ciência e a Tecnologia (CEEC position, 2019–2025 investigator). This article is a Fiigureresult of the projects (iNOVA4Health— UIDB/04462/2020), supported by Lisboa Portugal Regional Operational Programme (Lisboa2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). This work is also funded by FEDER funds through the COMPETE 2020 Programme and National Funds through FCT—Portuguese Foundation for Science and Technology under the project numbers: PTDC/BTM-TEC/30087/2017 and PTDC/BTM-TEC/30088/2017.
publishDate 2023
dc.date.none.fl_str_mv 2023-01-18T22:17:08Z
2023-01-03
2023-01-03T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/147811
url http://hdl.handle.net/10362/147811
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2073-4409
PURE: 50623021
https://doi.org/10.3390/cells12010196
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv mluisa.alvim@gmail.com
_version_ 1817545910292316160

Registros relacionados